TYF administration significantly reduced tumor growth and metastatic burden without detectable systemic toxicity <i>in vivo</i>.<h4>Conclusion</h4>TYF exhibits anti-TNBC activity through EGFR and AXL inhibition and suppression of metastatic potential. This evidence concerns the gene AXL and neoplasm.